Comparison of FDA (2018) and EAEU Regulatory Requirements for Bioanalytical Method Validation
- 作者: Uvarova N.E.1, Eremenko N.N.1,2, Ramenskaya G.V.1,2, Goryachev D.V.1, Smirnov V.V.1,2
- 
							隶属关系: 
							- Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation
- I. M. Sechenov First Moscow State Medical University (Sechenov University)
 
- 期: 卷 53, 编号 8 (2019)
- 页面: 759-765
- 栏目: Structure of Chemical Compounds, Methods of Analysis and Process Control
- URL: https://ogarev-online.ru/0091-150X/article/view/245986
- DOI: https://doi.org/10.1007/s11094-019-02075-z
- ID: 245986
如何引用文章
详细
US FDA requirements published in the new 2018 guidance for bioanalytical method validation and the necessity to confirm their reliability for determining analyte concentrations are reviewed. The history of regulations for bioanalytical method validation is briefly described. The key changes and additions to the FDA guidance for bioanalytical method validation that include unified requirements for chromatographic and ligand-binding method validation, instructions for biomarker validation, a separate section focused on new technologies (e.g., dry blood-spot method), and introduction of the fit-for-purpose concept are discussed. FDA and EAEU requirements for validation of chromatographic assay parameters are compared. In general, the requirements of the new FDA guidance and the EAEU agree despite several differences in the number of parameters and their acceptance criteria.
作者简介
N. Uvarova
Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation
							编辑信件的主要联系方式.
							Email: uvarova@expmed.ru
				                					                																			                												                	俄罗斯联邦, 							8/2 Petrovskii Blvd., Moscow, 127051						
N. Eremenko
Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation; I. M. Sechenov First Moscow State Medical University (Sechenov University)
														Email: uvarova@expmed.ru
				                					                																			                												                	俄罗斯联邦, 							8/2 Petrovskii Blvd., Moscow, 127051; 8/2 Trubetskaya St., Moscow, 119991						
G. Ramenskaya
Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation; I. M. Sechenov First Moscow State Medical University (Sechenov University)
														Email: uvarova@expmed.ru
				                					                																			                												                	俄罗斯联邦, 							8/2 Petrovskii Blvd., Moscow, 127051; 8/2 Trubetskaya St., Moscow, 119991						
D. Goryachev
Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation
														Email: uvarova@expmed.ru
				                					                																			                												                	俄罗斯联邦, 							8/2 Petrovskii Blvd., Moscow, 127051						
V. Smirnov
Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation; I. M. Sechenov First Moscow State Medical University (Sechenov University)
														Email: uvarova@expmed.ru
				                					                																			                												                	俄罗斯联邦, 							8/2 Petrovskii Blvd., Moscow, 127051; 8/2 Trubetskaya St., Moscow, 119991						
补充文件
 
				
			 
						 
						 
					 
						 
						 
				 
  
  
  
  
  电邮这篇文章
			电邮这篇文章  开放存取
		                                开放存取 ##reader.subscriptionAccessGranted##
						##reader.subscriptionAccessGranted## 订阅存取
		                                		                                        订阅存取
		                                					